

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**PARRY ROMANI DECONCINI & SYMMS**

2. Address:

517 C ST NE, WASHINGTON, DC 20002

3. Principal place of business (if different from line 2):

4. Contact Name: MICHELLE MAGOON

Telephone: 202-547-4000

E-mail (optional): mmagoon@lobbycongress.com

Senate ID #: 30792-1888

House ID #: 30115134

7. Client Name: ☐ Self

**CHIRON CORP**

## TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): \_\_\_\_\_

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 2744: Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for the fiscal year ending September 30, 2006, and for other purposes. H.R. 3010: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and Related Agencies for the fiscal year ending September 30, 2006, and for other purposes. Lobbied for sufficient funding of the CDC and NIH. H.R. 2601: To authorize appropriations for the Department of State for Fiscal Years 2006 and 2007. Lobbied for sufficient funding for bioterrorist medical counter measures. H.R. 2863: Department of Defense Appropriations Act, 2006. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. Funds for domestic vaccine supply, Centers for Disease Control, National Institutes of Health and Vaccine Injury Compensation Fund.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention  
Centers For Disease Control & Prevention  
HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Health & Human Services, Dept of (HHS)  
Natl Institutes of Health (NIH)  
Natl Institutes of Health (NIH)  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 2744: Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for the fiscal year ending September 30, 2006, and for other purposes. H.R. 3010: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and Related Agencies for the fiscal year ending September 30, 2006, and for other purposes. Lobbied for sufficient funding of the CDC and NIH. H.R. 2601: To authorize appropriations for the Department of State for Fiscal Years 2006 and 2007. Lobbied for sufficient funding for bioterrorist medical counter measures. H.R. 2863: Department of Defense Appropriations Act, 2006. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. Funds for domestic vaccine supply, Centers for Disease Control, National Institutes of Health and Vaccine Injury Compensation Fund.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention  
Centers For Disease Control & Prevention  
HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Health & Human Services, Dept of (HHS)  
Natl Institutes of Health (NIH)  
Natl Institutes of Health (NIH)  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect intellectual property rights. H.R. 2791: To amend title 35, United States Code, with respect to patent fees, and for other purposes. Lobbied for reasonable patent fees and to protect intellectual property rights. H.R. 357, S. 167: To provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4102: To amend title 35, United States Code, to provide for compulsory licensing of certain patented inventions relating to health care emergencies. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4131: To amend title 35, United States Code, to provide for compulsory licensing of certain patented inventions relating to health care emergencies, and to provide that applications under section 505 of the Federal Food, Drug, and Cosmetic Act that are submitted pursuant to such licenses may be approved with immediate effective dates. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4392: To provide for the importation of pharmaceutical products under a compulsory license as provided for under the World Trade Organization. Lobbied to protect the Biopharmaceutical industry's intellectual imports, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S.Amdt. to H.R. 2862: To prevent the United States Trade Representative from negotiating future trade agreements that prevent the United States from changing United States patent law to allow the importation of pharmaceutical products. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S. 1511: A bill to clarify that the overall trade negotiating objectives of the United States include avoiding provisions in trade agreements that restrict the access of consumers in the United States to pharmaceutical products.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect intellectual property rights. H.R. 2791: To amend title 35, United States Code, with respect to patent fees, and for other purposes. Lobbied for reasonable patent fees and to protect intellectual property rights. H.R. 357, S. 167: To provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4102: To amend title 35, United States Code, to provide for compulsory licensing of certain patented inventions relating to health care emergencies. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4131: To amend title 35, United States Code, to provide for compulsory licensing of certain patented inventions relating to health care emergencies, and to provide that applications under section 505 of the Federal Food, Drug, and Cosmetic Act that are submitted pursuant to such licenses may be approved with immediate effective dates. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4392: To provide for the importation of pharmaceutical products under a compulsory license as provided for under the World Trade Organization. Lobbied to protect the Biopharmaceutical industry's intellectual imports, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S.Amdt. to H.R. 2862: To prevent the United States Trade Representative from negotiating future trade agreements that prevent the United States from changing United States patent law to allow the importation of pharmaceutical products. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S. 1511: A bill to clarify that the overall trade negotiating objectives of the United States include avoiding provisions in trade agreements that restrict the access of consumers in the United States to pharmaceutical products.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S. 16: A bill to reduce to the cost of quality health care coverage and improve the availability of health care coverage for all Americans. Lobbied to protect the interests of the Biotech drug industry. S. 109, H.R. 328: A bill entitled the "Pharmaceutical Market Access Act of 2005". Lobbied for an exemption for biologics. S. 184, H.R. 753: A bill to amend the Federal Food, Drug, and Cosmetic Act to protect the public health from the unsafe importation of prescription drugs and from counterfeit prescription drugs, and for other purposes. Lobbied for an exemption for biologics. S. 334, H.R. 700: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 563: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate and disclose lowest possible prices for prescription drug prices for Medicare beneficiaries, and with respect to the Federal Food, Drug, and Cosmetic Act, to provide waivers that permit such beneficiaries to import prescription drugs from Canada. Lobbied for an exemption for biologics. H.R. 578: To amend the Internal Revenue Code of 1986 with respect to the purchase of prescription drugs by individuals who have attained retirement age, and to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs and the sale of such drugs through Internet sites. Lobbied for an exemption for biologics. H.R. 1626: To amend part D of the title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negotiate for lower prices for Medicare prescription drugs and to eliminate the gap in coverage of Medicare prescription drug benefits, to the Secretary of Health and Human Services to promulgate regulations for the reimportation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 2599: To improve the quality, availability, diversity, personal privacy, and innovation of health care in the United States. Lobbied for an exemption for biologics. H.R. 16: To authorize the use of Federal funds for research on human embryonic stem cells irrespective of the date on which such stem cells were derived, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 596, S. 681: To amend the Public Health Service Act to establish a National Cord Blood Stem Cell Bank. Network to prepare, store, and distribute human umbilical cord blood stem cells for the treatment of patients and to support peer-reviewed research using such cells. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 810, S. 471: To amend the Public Health Service Act to provide for human embryonic stem cell research. H.R. 1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 1822, S. 876: To prohibit human cloning and protect stem cells research. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2541: To amend the Public Health Service Act to provide for the expansion, intensification, and coordination of the activities of the National Institutes of Health regarding qualifying adult stem cell research, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2520, S. 1317: To provide for the collection and maintenance of human cord blood stem cells for the treatment of patients and research, and to amend the Public Health Service Act to authorize the C.W. Bill Young Cell Transplantation Program. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2574: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos that do not harm the embryos, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S. 1392: A bill to reauthorize the Federal Trade Commission. (Dorgan/Snowe Drug Importation Amendment). Lobbied for an exemption for biologics. H.R. 3144: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research in the derivation and use of human pluripotent stem cells by means that do not harm human embryos, and for other purposes. Lobbied for the interests of the vaccine industry. H.R. 3423, S. 1420: To amend the Federal Food, Drug, and Cosmetic Act with respect to medical device user fees. Lobbied for the interests of the medical device industry. S. 226: A bill to amend the Public Health Service Act to improve immunization rates by increasing the supply of vaccines. Lobbied for the interest of the vaccine industry. S. 521, H.R. 1290: A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive prevention, research, and medical management referral program for hepatitis C virus infection. Supported bill. S. 969, H.R. 3369: A bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. Lobbied for the interests of the vaccine industry. S. 1422, H.R. 881: A bill to amend the Federal Food, Drug, and Cosmetic Act to reduce human exposure to mercury through vaccines. Lobbied for the interests of the vaccine industry. H.R. 650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines, and for other purposes. Lobbied for the interests of the vaccine industry. H.R. 1297: To amend the Public Health Service Act with respect to the National Vaccine Injury Compensation Program. Lobbied for the interests of the vaccine industry. S. 930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S. 470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to provide the best information to the patient. H.R. 2090: To amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug Administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes. Lobbied for provisions that promoted the development safe and effective drugs. H.R. 2124, H.R. 2308: To amend the Public Health Service Act to provide for clinical research support grants, clinical research infrastructure grants, and a demonstration program on partnerships in clinical research, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. H.R. 2650: To amend the Public

Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to protect consumers in managed care plans and other health coverage. Lobbied for the interests of the industry. H.R.2792: To permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests, and for other purposes. Lobbied for the interests of the industry. H.R.3196,H.R.2259,S.1012: To amend the Public Health Service Act to expand the scope of information required for the data bank on clinical trials of drugs, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. S.1128: A bill to amend title XIX of the Social Security Act to provide for increased rebates under the medicaid program for prescription drugs that are directly advertised to consumers, to require other Federal programs purchasing or reimbursing for such drugs to establish payment and reimbursement mechanisms that reduce the costs of those drugs, and for other purposes. Lobbied to ensure that any enacted restrictions would not impede access of the consumer to accurate information about pharmaceutical products. H.R.840,S.399: A bill to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.1808,S.334: To amend the Federal Food, Drug, and Cosmetic Act to create a uniform certification standard for Internet pharmacies and to prohibit Internet pharmacies from engaging in certain advertising activities, to prohibit the use of certain bank instruments for purchases associated with illegal Internet pharmacies, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.4395: To amend titles XVIII and XIX of the Social Security Act to provide for an improved voluntary Medicare prescription drug benefit, to provide greater access to affordable pharmaceuticals, and for other purposes. Lobbied for an exemption for biologics in the Drug Importation section. S.470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R.2345: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. Lobbied in support of enhanced FDA authorities over counterfeit products. H.R.3052,S.1527: Vaccine Access and Supply Act, lobbied for provisions to strengthen the domestic vaccine industry. H.R.3970: Bioterror and Pandemic Preparedness Protection Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1821: Pandemic Preparedness and Response Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1828: Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure as strong domestic vaccine industry. S.1912: Global Network for Avian Influenza Surveillance Act, lobbied in support of domestic pandemic preparedness. S.375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stabilize production and supply. S.969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions. General matters related to vaccine industry stability, pandemic preparedness, avian influenza.

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Health & Human Services, Dept of (HHS)  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S. 16: A bill to reduce to the cost of quality health care coverage and improve the availability of health care coverage for all Americans. Lobbied to protect the interests of the Biotech drug industry. S. 109, H.R. 328: A bill entitled the "Pharmaceutical Market Access Act of 2005". Lobbied for an exemption for biologics. S. 184, H.R. 753: A bill to amend the Federal Food, Drug, and Cosmetic Act to protect the public health from the unsafe importation of prescription drugs and from counterfeit prescription drugs, and for other purposes. Lobbied for an exemption for biologics. S. 334, H.R. 700: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 563: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate and disclose lowest possible prices for prescription drug prices for Medicare beneficiaries, and with respect to the Federal Food, Drug, and Cosmetic Act, to provide waivers that permit such beneficiaries to import prescription drugs from Canada. Lobbied for an exemption for biologics. H.R. 578: To amend the Internal Revenue Code of 1986 with respect to the purchase of prescription drugs by individuals who have attained retirement age, and to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs and the sale of such drugs through Internet sites. Lobbied for an exemption for biologics. H.R. 1626: To amend part D of the title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negotiate for lower prices for Medicare prescription drugs and to eliminate the gap in coverage of Medicare prescription drug benefits, to the Secretary of Health and Human Services to promulgate regulations for the reimportation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 2599: To improve the quality, availability, diversity, personal privacy, and innovation of health care in the United States. Lobbied for an exemption for biologics. H.R. 16: To authorize the use of Federal funds for research on human embryonic stem cells irrespective of the date on which such stem cells were derived, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 596, S. 681: To amend the Public Health Service Act to establish a National Cord Blood Stem Cell Bank. Network to prepare, store, and distribute human umbilical cord blood stem cells for the treatment of patients and to support peer-reviewed research using such cells. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 810, S. 471: To amend the Public Health Service Act to provide for human embryonic stem cell research. H.R. 1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 1822, S. 876: To prohibit human cloning and protect stem cells research. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2541: To amend the Public Health Service Act to provide for the expansion, intensification, and coordination of the activities of the National Institutes of Health regarding qualifying adult stem cell research, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2520, S. 1317: To provide for the collection and maintenance of human cord blood stem cells for the treatment of patients and research, and to amend the Public Health Service Act to authorize the C.W. Bill Young Cell Transplantation Program. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2574: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos that do not harm the embryos, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S. 1392: A bill to reauthorize the Federal Trade Commission. (Dorgan/Snowe Drug Importation Amendment). Lobbied for an exemption for biologics. H.R. 3144: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research in the derivation and use of human pluripotent stem cells by means that do not harm human embryos, and for other purposes. Lobbied for the interests of the vaccine industry. H.R. 3423, S. 1420: To amend the Federal Food, Drug, and Cosmetic Act with respect to medical device user fees. Lobbied for the interests of the medical device industry. S. 226: A bill to amend the Public Health Service Act to improve immunization rates by increasing the supply of vaccines. Lobbied for the interest of the vaccine industry. S. 521, H.R. 1290: A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive prevention, research, and medical management referral program for hepatitis C virus infection. Supported bill. S. 969, H.R. 3369: A bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. Lobbied for the interests of the vaccine industry. S. 1422, H.R. 881: A bill to amend the Federal Food, Drug, and Cosmetic Act to reduce human exposure to mercury through vaccines. Lobbied for the interests of the vaccine industry. H.R. 650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines, and for other purposes. Lobbied for the interests of the vaccine industry. H.R. 1297: To amend the Public Health Service Act with respect to the National Vaccine Injury Compensation Program. Lobbied for the interests of the vaccine industry. S. 930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S. 470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to provide the best information to the patient. H.R. 2090: To amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes. Lobbied for provisions that promoted the development safe and effective drugs. H.R. 2124, H.R. 2308: To amend the Public Health Service Act to provide for clinical research support grants, clinical research infrastructure grants, and a demonstration program on partnerships in clinical research, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. H.R. 2650: To amend the Public



Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to protect consumers in managed care plans and other health coverage. Lobbied for the interests of the industry. H.R.2792: To permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests, and for other purposes. Lobbied for the interests of the industry. H.R.3196,H.R.2259,S.1012: To amend the Public Health Service Act to expand the scope of information required for the data bank on clinical trials of drugs, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. S.1128: A bill to amend title XIX of the Social Security Act to provide for increased rebates under the medicaid program for prescription drugs that are directly advertised to consumers, to require other Federal programs purchasing or reimbursing for such drugs to establish payment and reimbursement mechanisms that reduce the costs of those drugs, and for other purposes. Lobbied to ensure that any enacted restrictions would not impede access of the consumer to accurate information about pharmaceutical products. H.R.840,S.399: A bill to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.1808,S.334: To amend the Federal Food, Drug, and Cosmetic Act to create a uniform certification standard for Internet pharmacies and to prohibit Internet pharmacies from engaging in certain advertising activities, to prohibit the use of certain bank instruments for purchases associated with illegal Internet pharmacies, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.4395: To amend titles XVIII and XIX of the Social Security Act to provide for an improved voluntary Medicare prescription drug benefit, to provide greater access to affordable pharmaceuticals, and for other purposes. Lobbied for an exemption for biologics in the Drug Importation section. S.470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R.2345: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. Lobbied in support of enhanced FDA authorities over counterfeit products. H.R.3052,S.1527: Vaccine Access and Supply Act, lobbied for provisions to strengthen the domestic vaccine industry. H.R.3970: Bioterror and Pandemic Preparedness Protection Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1821: Pandemic Preparedness and Response Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1828: Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure as strong domestic vaccine industry. S.1912: Global Network for Avian Influenza Surveillance Act, lobbied in support of domestic pandemic preparedness. S.375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stabilize production and supply. S.969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions. General matters related to vaccine industry stability, pandemic preparedness, avian influenza.

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Health & Human Services, Dept of (HHS)  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HOM (one per page)

16. Specific lobbying issues:

S. 3: A bill to strengthen and protect America in the war on terror. Lobbied for incentives to manufacture biomedical counter measures.  
S. 975: A bill to provide incentives to increase research by private sector entities to develop medical counter measures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak, and for pandemic preparedness provisions. S. 1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R. 1815, S. 1042: National Defense Authorizations Act for Fiscal Year 2006. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R. 2601: To authorize appropriations for the Department of State for Fiscal Years 2006 and 2007. Lobbied for sufficient funding for bioterrorist medical counter measures.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention  
Centers For Disease Control & Prevention  
HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Health & Human Services, Dept of (HHS)  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HOM (one per page)

16. Specific lobbying issues:

S. 3: A bill to strengthen and protect America in the war on terror. Lobbied for incentives to manufacture biomedical counter measures.  
S. 975: A bill to provide incentives to increase research by private sector entities to develop medical counter measures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak, and for pandemic preparedness provisions. S. 1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R. 1815, S. 1042: National Defense Authorizations Act for Fiscal Year 2006. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R. 2601: To authorize appropriations for the Department of State for Fiscal Years 2006 and 2007. Lobbied for sufficient funding for bioterrorist medical counter measures.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention  
Centers For Disease Control & Prevention  
HOUSE OF REPRESENTATIVES  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
Health & Human Services, Dept of (HHS)  
SENATE  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

S. 96: A bill to target Federal funding for research and development, to amend section 1928 of the Social Security Act to encourage the production of influenza vaccines by eliminating the price cap applicable to the purchase of such vaccines under contracts entered into by the Secretary of Health and Human Services, to amend the Internal Revenue Code of 1986 to establish a tax credit to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. H.R. 628, H.R. 813: To amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375, H.R. 628, H.R. 813: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for incentives for the vaccine industry. S. 627: A bill to amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied for the R & D Tax credit. H.R. 1736: To amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 2943, S. 1263: To amend the Small Business Act to establish eligibility requirements for business concerns to receive awards under the Small Business Innovation Research Program. Lobbied for small business interests. H.R. 3154: To provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease, and for other purposes. Lobbied for incentives for the vaccine industry. H.R. 913: To direct the Securities and Exchange Commission to require enhanced disclosures of employee stock options, and to require a study on the economic impact of broad-based employee stock option plans, and for other purposes. Lobbied for the interests of the Biotech Medical Products industry. H.R. 1234: To amend the Internal Revenue Code of 1986 to require greater transparency of corporate tax accounting measures, to facilitate analysis of financial statements, to permit inspection of true corporate tax liability and understand the tax strategies undertaken by corporations, to discourage abusive tax sheltering activities, and to restore investor confidence in publicly traded corporations. Lobbied for the interest of the Biotech Medical products industry. S. 1008: A bill to amend the Internal Revenue Code of 1986 to add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund. Lobbied for incentives for the vaccine industry.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

HOUSE OF REPRESENTATIVES

SENATE

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD

Covered Official Position (if applicable):

Name: DECONCINI, DENNIS

Covered Official Position (if applicable):

Name: HADDOW, JOHN

Covered Official Position (if applicable):

Name: ROCK, JAMES

Covered Official Position (if applicable):

Name: ROMANI, ROMANO

Covered Official Position (if applicable):

Name: STROM, THADDEUS

Covered Official Position (if applicable):

Name: SYMMS, STEVE

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

S. 96: A bill to target Federal funding for research and development, to amend section 1928 of the Social Security Act to encourage the production of influenza vaccines by eliminating the price cap applicable to the purchase of such vaccines under contracts entered into by the Secretary of Health and Human Services, to amend the Internal Revenue Code of 1986 to establish a tax credit to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. H.R. 628, H.R. 813: To amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375, H.R. 628, H.R. 813: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for incentives for the vaccine industry. S. 627: A bill to amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied for the R & D Tax credit. H.R. 1736: To amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 2943, S. 1263: To amend the Small Business Act to establish eligibility requirements for business concerns to receive awards under the Small Business Innovation Research Program. Lobbied for small business interests. H.R. 3154: To provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease, and for other purposes. Lobbied for incentives for the vaccine industry. H.R. 913: To direct the Securities and Exchange Commission to require enhanced disclosures of employee stock options, and to require a study on the economic impact of broad-based employee stock option plans, and for other purposes. Lobbied for the interests of the Biotech Medical Products industry. H.R. 1234: To amend the Internal Revenue Code of 1986 to require greater transparency of corporate tax accounting measures, to facilitate analysis of financial statements, to permit inspection of true corporate tax liability and understand the tax strategies undertaken by corporations, to discourage abusive tax sheltering activities, and to restore investor confidence in publicly traded corporations. Lobbied for the interest of the Biotech Medical products industry. S. 1008: A bill to amend the Internal Revenue Code of 1986 to add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund. Lobbied for incentives for the vaccine industry.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

HOUSE OF REPRESENTATIVES

SENATE

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD

Covered Official Position (if applicable):

Name: DECONCINI, DENNIS

Covered Official Position (if applicable):

Name: HADDOW, JOHN

Covered Official Position (if applicable):

Name: ROCK, JAMES

Covered Official Position (if applicable):

Name: ROMANI, ROMANO

Covered Official Position (if applicable):

Name: STROM, THADDEUS

Covered Official Position (if applicable):

Name: SYMMS, STEVE

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PARRY ROMANI DECONCINI & SYMMS Client Name: CHIRON CORP

Signature: ON FILE Date: Feb 10, 2006

Printed Name and Title: Romano Romani, President -



**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

MED MED

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE Date: Feb 10, 2006

Printed Name and Title: ROMANO ROMANI, PRESIDENT -